12:00 AM
Oct 26, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AP214: Phase II started

Action Pharma began a double-blind, placebo-controlled, Danish Phase II trial to evaluate intravenous AP214 in 42 patients undergoing cardiac surgery. The company licensed...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >